We tested for enrichment of fine-mapped T2D risk variants from the DIAMANTE consortium for beta cell cCREs defining the beta-1 and beta-2 subtype as well as cCREs with differential activity in T2D. For each set of cCREs, we calculated the cumulative posterior probability of association (cPPA) of all fine-mapped variants overlapping cCREs. We then generated a null distribution of cPPA by randomly selecting the same number of cCREs from the set of all beta cell cCREs across 100,000 permutations. We calculated a p-value as the number of permutations with a higher cPPA than for the observed set of cCREs. We further computed an odds ratio as cPPAobs*(cPPAmax-cPPAmean)/cPPAmean*(cPPAmax-cPPAobs), where cPPAobs was the observed cPPA, cPPAmax is the maximum possible cPPA for that number of sites and cPPAmean is the average cPPA from the null distribution, and took the natural log of the odds ratio.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.